Revelation Biosciences In... (REVB)
Revelation Biosciences Inc. (REVB) Stock Price, Analysis & Data
| Bid | 0.81 |
| Market Cap | 4.1M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.2M |
| Beta | -0.17 |
| EPS (ttm) | 27.03 |
| PE Ratio (ttm) | 0.04 |
| Forward PE | -0.36 |
| P/B (ttm) | 0.32 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 5, 2026 |
| Ask | 1.35 |
| Volume | 31,073 |
| Avg. Volume (20D) | 40,845 |
| Open | 1.10 |
| Previous Close | 1.11 |
| Day's Range | 1.04 - 1.14 |
| 52-Week Range | 0.88 - 11.72 |
| Analyst | Strong Buy |
| Price Target | 17.75 (1590.48%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About REVB
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the ...
Financial Performance
In 2025, Revelation Biosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -8.91M, a decrease of -40.73%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for REVB stock is "Strong Buy". The 12-month stock price forecast is 17.75, which is upside of 1590.48% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade